by Steven Ertelt
August 2, 2005
Merced, CA (LifeNews.com) — Pro-life advocates in the central California town of Merced are upset that the nation’s largest abortion business has plans to build a new facility in their hometown. However, officials at Planned Parenthood say no abortions are planned there yet.
The proposed building is next to Merced High School, which has further upset pro-life advocates. They staged a rally against the building in Merced’s Courthouse Park and marched to city hall.
A current Planned Parenthood facility exists in downtown and officials say it will be moved to the new location.
"If we put this right next to the school, there’s going to be an abortion clinic next to the school. That’s just not compatible with the school," said Alan Enterreiner, who opposes the Planned Parenthood.
But Planned Parenthood’s Kathy Bright told ABC News 30 that no abortions are planned there.
"Abortion is not a service provided by [our] Planned Parenthood and hasn’t been in the last 22 years. And we have no plans for providing that service," she said.
Planned Parenthood has already purchased the land and Bright told ABC News 30 that the facility is next to the high school only because its a central location for their customers.
Planned Parenthood in California has come under fire for giving women the dangerous abortion drug RU 486, which has been responsible for the deaths of five women, including four in the state.
The abortion business has been accused of not following FDA protocols, including using wrong doses of the abortion drug and misusing the ulcer drug misoprostol to cause a miscarriage of the dead baby.
It also sometimes instructs women to insert the drug vaginally while FDA guidelines call for oral use.
Searle, the maker of the ulcer drug, issued a nationwide letter to doctors years ago saying it is not intended to produce an abortion and using it as such places women’s health at risk.
All four of the California deaths occurred in cases where the abortion drug was being used "off label" in an inconsistent manner with FDA protocols, the agency said.